伴中心静脉狭窄透析患者:下肢通路与HeRO移植物的比较
该回顾性研究纳入2015至2022年一家大型安全网医院伴有中心静脉狭窄的25例透析患者,比较下肢透析通路与上肢HeRO移植物的结局。HeRO组1年死亡率显著更高(55% vs. 6%,P=0.006),而1年初级通畅率(44% vs. 25%,P=0.21)和次级通畅率(56% vs. 44%,P=0.57)无显著差异。作者认为HeRO移植物是中心静脉狭窄患者下肢通路的可接受替代选择,尤其适用于合并外周动脉疾病者。
要点
- HeRO组1年死亡率显著高于下肢通路组(55% vs. 6%,P=0.006)。
- 1年初级通畅率下肢通路组较高但无统计学差异(44% vs. 25%,P=0.21)。
- 1年次级通畅率两组无差异(56% vs. 44%,P=0.57),HeRO可作为下肢通路的替代选择。
核心结论
- 上肢HeRO移植物与下肢AV通路在初级和次级通畅率方面结局相似。
- HeRO移植物是中心静脉狭窄患者下肢通路的可接受替代选择,尤其适用于合并外周动脉疾病者。
研究设计与样本
- 回顾性分析2015至2022年一家大型安全网医院伴有中心静脉狭窄、接受下肢透析通路或HeRO移植物置入的患者。
- 共纳入25例患者。
- 主要结局为1年初级通畅率、次级通畅率和死亡率,次要结局为术后30天结局。
主要发现
- HeRO组外周动脉疾病比例更高但无统计学差异(33% vs. 6%,P=0.12)。
- HeRO组1年死亡率显著更高(55% vs. 6%,P=0.006)。
- 下肢通路组1年初级通畅率较高但无统计学差异(44% vs. 25%,P=0.21)。
- 两组1年次级通畅率无差异(56% vs. 44%,P=0.57)。
临床怎么用
- 中心静脉狭窄患者选择透析通路时,HeRO移植物可作为下肢通路的替代方案。
- 对合并外周动脉疾病、不适合下肢通路的患者,可考虑HeRO移植物。
- 决策时需结合本研究所示HeRO组1年死亡率较高的信号个体化评估。
局限性
- 样本量小(25例),结果受限。
- 为单中心回顾性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with central venous stenosis, it is controversial whether an upper extremity Hemodialysis Reliable Outflow (HeRO) graft or lower extremity access is preferable. Furthermore, lower extremity grafts are contraindicated in patients with significant peripheral artery disease. The purpose of this study was to compare outcomes of HeRO grafts with lower extremity dialysis access in patients with central venous stenosis. METHODS: We performed a retrospective analysis of patients with central venous stenosis undergoing lower extremity dialysis access or HeRO graft placement at a large safety-net hospital from 2015 to 2022. Primary outcomes were 1-year primary patency, secondary patency, and mortality. Secondary outcomes were 30-day postoperative outcomes. RESULTS: There were 25 patients included in this study. There was a higher rate of peripheral arterial disease in the patients undergoing HeRO graft placement, although not significant (33% vs. 6%, P = 0.12). One year mortality was significantly higher for patients who underwent HeRO graft (55% vs. 6%, P = 0.006). 1-year primary patency was higher for lower extremity access, although not significant (44% vs. 25%, P = 0.21). There was no difference in secondary patency at 1 year between HeRO grafts and lower extremity access (56% vs. 44%, P = 0.57). CONCLUSION: Although our results are limited by small sample size, upper extremity HeRO grafts appear to have similar outcomes compared to lower extremity AV access in terms of primary and secondary patency. Thus, HeRO grafts are an acceptable alternative to lower extremity access in patients with central venous stenosis, particularly in patients who have peripheral artery disease who may not be candidates for lower extremity access.
引用
- Mehta V, Curry J, DeVirgilio C, et al. Lower Extremity Access versus HeRO Graft: Choosing Dialysis Access in Patients with Central Venous Stenosis. Ann Vasc Surg. 2026. PMID: 42342210. doi:10.1016/j.avsg.2026.05.118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。